<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

The effect of antidepressant medication use on HbA1c levels in type 2 diabetes

dc.contributor.authorSaglam, Fatih
dc.contributor.authorNas, Necip
dc.contributor.authorSaglik, Semih
dc.date.accessioned2026-03-14T11:49:07Z
dc.date.available2026-03-14T11:49:07Z
dc.date.issued2026
dc.departmentSiirt Üniversitesi
dc.description.abstractBackground: Chronic psychological symptoms such as anxiety and depression are known to negatively affect glycemic control in patients with type 2 diabetes (T2D). However, the impact of psychiatric treatment on glycemic outcomes remains underexplored. Objective: This study aimed to evaluate the effect of psychiatric treatment on HbA1c levels in T2D patients presenting with psychological symptoms. Methods: A total of 64 T2D patients with psychological complaints were retrospectively analyzed and divided into two groups based on psychiatric treatment status: 39 patients received antidepressant therapy, while 25 did not. Demographic data, comorbidities, and HbA1c levels before and after treatment or during follow-up were compared between groups. Statistical analyses were performed to assess differences in HbA1c changes. Results: There were no significant differences between groups regarding age, gender, or comorbid medical conditions (p>0.05). Patients receiving psychiatric treatment showed a significant reduction in HbA1c levels compared to those untreated (37.5% vs. 9.4% HbA1c decrease, p<0.001). Conversely, HbA1c levels increased in a higher proportion of untreated patients (28.1% vs. 15.6%). The reduction in HbA1c was more pronounced in individuals with baseline HbA1c levels above 8%. Patients treated with SSRIs, particularly sertraline and escitalopram, showed notable reductions in HbA1c levels. Conclusion: Our study suggests that antidepressant therapy in patients with depressive symptoms may contribute to reductions in HbA1c levels. This finding supports the notion that targeted treatment of depression can positively influence glycemic control. These results underscore the importance of integrating depression screening and management into T2D care strategies. Further longitudinal and large-scale studies are warranted to confirm these findings and clarify the mechanisms underlying the psychometabolic effects of antidepressants.
dc.identifier.doi10.3389/fpsyt.2025.1693817
dc.identifier.issn1664-0640
dc.identifier.pmid41601512
dc.identifier.scopus2-s2.0-105028485586
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3389/fpsyt.2025.1693817
dc.identifier.urihttps://hdl.handle.net/20.500.12604/9099
dc.identifier.volume16
dc.identifier.wosWOS:001670768700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260310
dc.subjectAntidepressants
dc.subjectGlycemic Control
dc.subjectHba1C
dc.subjectPsychiatric Symptoms
dc.subjectType 2 Diabetes
dc.titleThe effect of antidepressant medication use on HbA1c levels in type 2 diabetes
dc.typeArticle

Dosyalar